The latest market price of Datopotamab in 2025

Datopotamab (Datopotamab) is an antibody drug conjugate (ADC) targeting TROP2 . Its core feature is the dual mechanism of antibody precise recognition of tumor cells and cytotoxic load, which enhances penetration and reduces non-specific toxicity caused by traditional chemotherapy. The drug was first used overseas in research on the treatment of breast cancer and lung cancer, and then gradually expanded to a wider range of solid tumors. As the drug is launched around the world, its clinical use scenarios are becoming clearer. They are mainly concentrated in the patient group who have received multiple lines of treatment and whose disease continues to progress. Especially for those who are resistant to traditional chemotherapy and some targeted drugs, dabrotuzumab has become a new treatment option.

In terms of price, dabrotuzumab is a typical high-cost ADC drug, and its selling price in the global market is generally high. According to public channels, the price of the European version 100mg/ bottle is about more than 30,000 yuan, while the U.S. version can reach more than 60,000 yuan for the same specification due to differences in pricing strategies and supply systems, making it a more expensive variety in the high-end innovative drug system. Although it has been launched in China, the price is still in a volatile stage due to the influence of supply channels, exchange rates, taxes and circulation systems. Since it has not yet been included in medical insurance, in actual use, most patients will compare the purchase costs from different channels, including purchasing drugs from domestic original research, cross-border supply chains or designated medical institutions.

Currently, there are no generic drugs on the market worldwide. This is because ADC drugs have strong patent protection, high technical barriers, and complex preparation processes. They do not meet the conditions for being copied in the short term. Therefore, they are still exclusively supplied by the original manufacturer during the patent period. Judging from application trends, the potential indications of dedabrotumumab are continuing to expand, especially in the fields of lung cancer and breast cancer, and a number of key clinical studies have entered late stages.

Reference materials: https://www.google.com.hk/